Read Article

Supporting international business matching, LSMIP propritizes "Speed" and "Accuracy" in out service.
Please be noted that contents are in English/Japanese, translated on a request basis from authors/members.
国際間のビジネス・マッチングを促進するため、LSMIPでは情報発信の迅速性・正確性を重視しております。
コンテンツは各言語(英語、日本語)でお読みいただけますが、必要に応じて翻訳する場合があります。

Overview

0

[Yakuji Nippo]Ministers Agreed on Off-year Revision - Settled on Coverage of "Deviation Rate of More than 5%", Prices to be Reduced for 70% of All Products

Minister of Finance Taro Aso, Chief Cabinet Secretary Katsunobu Kato and Minister of Health, Labor and Welfare Norihisa Tamura discussed ...
  • Target market
    Japan
  • Business category
    Pharmaceutical, Biopharmaceutical, Regerative medicine, Medical device, Digital health, Others
  • Business function
    Marketing >
  • Keyword
  • Author
    "LSMIP Editorial Office" of "CM Plus Corporation"
  • Availability
    Membership

Detail


株式会社薬事日報社から許諾を受けて、株式会社シーエムプラスが英語に翻訳しております。
オリジナルの正式言語は日本語であり、内容および解釈については日本語が優先されます。
With permission from Yakuji Nippo, Limited, CM Plus Corporation translated into English.
The original article is authored in Japanese, and the Japanese shall prevail in meaning in terms of content and interpretation.

 

Ministers Agreed on Off-year Revision - Settled on Coverage of "Deviation Rate of More than 5%", Prices to be Reduced for 70% of All Products
December 21st, 2020

Minister of Finance Taro Aso, Chief Cabinet Secretary Katsunobu Kato and Minister of Health, Labor and Welfare Norihisa Tamura discussed the FY2021 budget on December 17, 2020 and agreed that the off-year revision of NHI prices in next April would cover products with a deviation rate of more than 5.0%, which is 0.625 time the average deviation rate 8%. The revision will apply to 12,000 items, or 69% of all products, and the price of each product will be reduced to the actual selling price added with 2.8% of the selling price consisting of 2% adjustment range of weighted average of selling prices and 0.8% "Special exception for new coronavirus infection." About 60% of new drugs and 80% of generic drugs will be affected and the expected reduction of drug cost will be about 430 billion yen (or about 100 billion yen on a national expenditure basis). (See a related article in Page 2.)

(Continue to the next)


For this translated article in English, CM Plus Corporation shall have the copyright.
Unauthorized reproduction of posted articles, photos, diagrams, etc. is prohibited.
Copyright © 2020 LSMIP office / CM Plus Singapore Pte. Ltd.

Comments (Require approval)

What information are you looking for in articles?
Let us help you to find out the articles for your business requirements!
Like many other companies, we use cookies and other technologies, some of which are essential to make our website work. By clicking Accept or continuing to use our site, you agree to use these cookies and other technologies. To learn more, check out our privacy policy.
Accept